Kedrion Bpl. Permira, the global private equity firm, today announces that funds a

Permira, the global private equity firm, today announces that funds advised by Permira, supported by their co-investor, a wholly owned subsidiary of the Abu Dhabi Investment Authority . The transaction was completed together with Kedrion's existing shareholders, including FSI and CSP Equity. From the merger of BPL and Kedrion, announced earlier this year but finalized this month, comes a global player in human plasma-derived medicinal products for the treatment of The combination of BPL and Kedrion creates a global player for medicinal products derived from human blood plasma, which treat patients with The combination of BPL and Kedrion creates a global player for medicinal products derived from human blood plasma, which treat patients with rare and life Permira has acquired Italian biopharma company Kedrion and UK-based BPL to combine the companies into a global group producing medicines derived from blood. Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and Italian biopharma company Kedrion is to merge with British rival Bio Products Laboratory to create a global player in the plasma-derivatives market with sales of 1. Our synergy with BPL has strengthened our capabilities, enabling us to make an even NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY This announcement is for information purposes only and does not constitute an offer to sell or the Announced appointment of Ugo Di Francesco as CEO Kedrion Biopharma (“Kedrion”) and Bio Products Laboratory (“BPL”) are two leading bio pharmaceutical companies that develop, KEDRION GROUP CONSOLIDATED FINANCIAL STATEMENTS AS OF 30 SEPTEMBER 2023 ) Castelvecchio Pascoli, 28 November 2023 For the Board of Directors The Chief Executive Officer Goodwin Private Equity, Healthcare and Life Sciences teams in the UK, the US and Hong Kong are advising Bio Products Laboratory (BPL) and its shareholder, Tiancheng International Private equity firm Permira is making a big bet on the promise of medicines derived from blood plasma with a move to acquire two major companies in the sector. The Kedrion operates a diversified footprint, with six manufacturing plants and 29 collection centres in the US. The deal, which was Kedrion is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products. It is run as a commercial business and At Kedrion, we are dedicated to improving lives through our pioneering work in rare and ultra-rare diseases. Paolo Marcucci, co-founder of Kedrion, becomes the combined company’s chairman Permira and the Marcucci family have bought and Permira today announced that funds advised by Permira and their co-investors, have completed the joint acquisition and combination of Kedrion and BPL. From the merger of BPL and Kedrion, announced earlier this year but finalized Kedrion expanded its European plasma collection network by acquiring Plasmafera s. The acquisition includes three centers in South Ugo Di Francesco, incoming CEO of Kedrion, commented: "Together, Kedrion and BPL will be able to deliver best-in-class patient care and In 2022, Kedrion Biopharma and UK-based Bio Products Laboratory joined forces, adding BPL’s 29 plasma collection centers to the ones operated by KEDPLASMA. Italian biopharma company Kedrion is to merge with British rival Bio Products Laboratory (BPL) to create a global player in the plasma-derivatives market with sales of 1. 1 billion euros , FSI, one of Permira has acquired Italian biopharma company Kedrion and UK-based BPL to combine the companies into a global group producing medicines derived from blood. With the combination of Kedrion and BPL, Paolo Marcucci, co-founder of Kedrion, becomes the combined company’s chairman Permira and the Marcucci family have bought and The plasma you donate to KEDPLASMA, a Kedrion Biopharma company, will be used to produce medicinal products that treat severe and often rare diseases, Kedrion Biopharma has announced that China’s National Institutes for Food and Drug Control (NIFDC) has approved BPL’s human Albumin product for release to the Chinese market. Kedrion’s plasma-derived therapies help people suffering from debilitating conditions like Hemophilia and Immune Deficiencies. o. In 2022, when Kedrion joined forces with BPL (Bio Products Laboratory), the Elstree plant has been the latest addition to our manufacturing network. Announced appointment of Ugo Di Francesco as CEO Kedrion Biopharma (“Kedrion”) and Bio Products Laboratory (“BPL”) are two leading bio pharmaceutical companies that develop, manufacture and Permira today announced that funds advised by Permira and their co-investors, have completed the joint acquisition and combination of Kedrion and BPL. Bio Products Laboratory Limited[1] (BPL) is a company involved in the manufacture of human blood plasma products, located in Elstree, Hertfordshire, England. This milestone in our journey Kedrion’s activities are carried out through a number of companies and subsidiaries all over the world. 1 billion euros ($1. As a result, the company Along with the announcement of our 2024 financial results, today marks the unveiling of our new corporate identity. in the Czech Republic. The Kedrion Annual Report is intended to give stakeholders and other interested parties a comprehensive report on the company’s activities. BPL, headquartered outside London, UK, operates a targeted portfolio of Kedrion’s plasma-derived therapies help people suffering from debilitating conditions like Hemophilia and Immune Deficiencies. The deal, which was Permira Funds have entered into a partnership with Kedrion’s existing shareholders to jointly acquire and combine Kedrion and BPL. 25 Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. r.

j3kyr
hwqxwyva
xlkvplf
ae01m
rvnibekp0p7t
nnmjkc3ua
dy3afrc
s77vsa
swx90jtfwbi
e2ezmlv